GO
Loading...

Allergan Inc

More

  • Allergan to shareholders: Ignore Pershing Square Friday, 11 Jul 2014 | 6:31 PM ET
    A vial of Allergan’s Botox is arranged next to boxes for a photograph at a doctor's office in Manhattan Beach, Calif.

    Allergan told its stockholders not to respond to Pershing Square Capital Management's proposal to replace a majority of the board.

  • July 11- Allergan Inc advised its stockholders to refrain from taking any action in response to Pershing Square Capital Management's proposal to replace a majority of the botox maker's board.

  • A look at 5 hedge fund stars of the future Thursday, 10 Jul 2014 | 11:29 AM ET
    Joshua Birnbaum

    While you might not know their names now, you will. They are five hedge fund stars of the future as identified by Institutional Investor.

  • Allergan fighting Ackman     Thursday, 10 Jul 2014 | 9:16 AM ET

    CNBC's David Faber discusses Bill Ackman's backing of Valeant's takeover bid for Allergan. Allergan CEO David Pyott has bone to pick with Ackman.

  • Sarepta to file for approval of Eteplirsen     Thursday, 10 Jul 2014 | 8:31 AM ET

    The muscular dystrophy drug seems to slow the decline in walking ability, reports CNBC's Meg Tirrell.

  • Allergan CEO comes out swinging     Thursday, 10 Jul 2014 | 6:24 AM ET

    CNBC's Meg Tirrell reports Allergan CEO David Pyott told "Mad Money" host Jim Cramer Valeant's he is keeping his options open on acquisitions.

  • Allergan CEO to Cramer: Our anti-Valeant plan Wednesday, 9 Jul 2014 | 6:36 PM ET
    Allergan Chief Executive David Pyott

    In his quest to fend off a hostile takeover attempt, has Allergan CEO David Pyott got something powerful up his sleeve?

  • 10 stocks on Jim Cramer’s radar, right now Wednesday, 9 Jul 2014 | 6:07 PM ET
    Jim Cramer on Mad Money.

    Uncertain how to put money to work in a market that continues to flirt with all-time highs? Jim Cramer has a few ideas. Ten of them.

  • Your first trade for Wednesday Tuesday, 8 Jul 2014 | 1:55 PM ET

    The "Fast Money" traders share their final trades of the day.

  • Pershing Square offers slate for Allergan board Monday, 7 Jul 2014 | 3:49 PM ET

    July 7- William Ackman's Pershing Square Capital Management proposed on Monday a slate of six directors for the board of Allergan Inc as the hedge fund presses forward with its $53 billion takeover bid with Valeant Pharmaceuticals International Inc for the Botox maker.

  • Ackman leads small group of hedge outperformers Monday, 7 Jul 2014 | 1:36 PM ET
    Bill Ackman

    The S&P 500 may have rallied 6 percent during the first half of the year, but the average hedge fund appears to have trailed that substantially.

  • Your first trade for Tuesday Monday, 7 Jul 2014 | 1:07 PM ET

    The "Fast Money" traders share their final trades of the day.

  • Pershing Square surges 25% in first half Thursday, 3 Jul 2014 | 1:15 PM ET
    Bill Ackman

    William Ackman's main fund climbed 25% during the first half of 2014, ranking him as one of the year's top hedge fund industry performers.

  • Strong gains in its top holdings, including Canadian Pacific, Air Products& Chemicals and Burger King Worldwide helped fuel the rise. Ackman has spent much of June trying to convince pharmaceutical company Allergan, in which he is the biggest investor, to sell itself to rival Valeant Pharmaceuticals, with which he is working to negotiate a deal.

  • BOSTON, July 1- Activist investor William Ackman has hired Credit Suisse in his fight to have Valeant Pharmaceuticals acquire Botox maker Allergan Inc., a person familiar with the matter said on Tuesday.

  • NEW YORK and LOS ANGELES, July 1- Allergan Inc may take on debt to buy back its own shares as part of a multi-faceted plan to thwart a $53 billion takeover bid by Valeant Pharmaceuticals International Inc and activist investor William Ackman.

  • TIMELINE-Ackman and Valeant maneuver for Allergan Tuesday, 1 Jul 2014 | 2:02 PM ET

    July 1- Valeant Pharmaceuticals International Inc has teamed up with Pershing Square Capital Management, led by activist investor William Ackman, to make a run at Botox maker Allergan Inc. Here are the details of some of the most interesting steps along the way.

  • NEW YORK and LOS ANGELES, July 1- Allergan Inc may take on debt to buy back its own shares as part of a multi-faceted plan to thwart a $53 billion takeover bid by Valeant Pharmaceuticals International Inc and activist investor William Ackman.

  • NEW YORK, June 30- Most investments came up winners in the first half of 2014, which came to a close on Monday with solid gains for U.S. stocks, U.S. Treasuries, muni bonds, oil and gold. Forest Labs +64.9 Keurig Green +65.0.

  • June 30- Allergan Inc said on Monday that the U.S. Food and Drug Administration would not approve its acute migraine aerosol treatment until certain concerns are addressed, but the agency approved a new use for its implantable eye drug, Ozurdex.